KPTI vs. QVCGA
KPTI (Karyopharm Therapeutics Inc.) and QVCGA (QVC Group Inc) are both stocks. KPTI operates in Biotechnology (Healthcare), while QVCGA operates in Internet Retail (Consumer Cyclical).
Performance
KPTI vs. QVCGA - Performance Comparison
Loading charts...
Returns By Period
KPTI
- 1D
- -6.39%
- 1M
- -1.62%
- YTD
- 15.49%
- 6M
- 44.31%
- 1Y
- 89.31%
- 3Y*
- -36.47%
- 5Y*
- -43.70%
- 10Y*
- -23.75%
QVCGA
- 1D
- 0.00%
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
KPTI vs. QVCGA - Yearly Performance Comparison
| 2026 (YTD) | |
|---|---|
KPTI Karyopharm Therapeutics Inc. | -6.70% |
QVCGA QVC Group Inc | 0.00% |
Fundamentals
KPTI:
$210.08M
QVCGA:
$2.75M
KPTI:
-$13.00
QVCGA:
-$302.09
KPTI:
0.84
QVCGA:
0.00
KPTI:
$151.12M
QVCGA:
$9.23B
KPTI:
$145.13M
QVCGA:
$2.89B
KPTI:
-$93.05M
QVCGA:
$789.00M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KPTI vs. QVCGA — Risk / Return Rank
KPTI
QVCGA
KPTI vs. QVCGA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and QVC Group Inc (QVCGA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KPTI | QVCGA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.22 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 1.86 | — | — |
| Martin ratioReturn relative to average drawdown | 4.59 | — | — |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KPTI | QVCGA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.95 | — | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.46 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.28 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.27 | — | — |
Drawdowns
KPTI vs. QVCGA - Drawdown Comparison
The maximum KPTI drawdown since its inception was -99.50%, which is greater than QVCGA's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for KPTI and QVCGA.
Loading charts...
Drawdown Indicators
| KPTI | QVCGA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.50% | 0.00% | -99.50% |
Max Drawdown (1Y)Largest decline over 1 year | -48.36% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -89.32% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -98.36% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.15% | — | — |
Current DrawdownCurrent decline from peak | -98.80% | 0.00% | -98.80% |
Average DrawdownAverage peak-to-trough decline | -75.28% | 0.00% | -75.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.53% | — | — |
Volatility
KPTI vs. QVCGA - Volatility Comparison
Loading charts...
Volatility by Period
| KPTI | QVCGA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.86% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 62.32% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 94.32% | 0.00% | +94.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.91% | 0.00% | +94.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.51% | 0.00% | +86.51% |
Dividends
KPTI vs. QVCGA - Dividend Comparison
Neither KPTI nor QVCGA has paid dividends to shareholders.
Financials
KPTI vs. QVCGA - Financials Comparison
This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and QVC Group Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KPTI vs. QVCGA - Profitability Comparison
KPTI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a gross profit of 33.72M and revenue of 35.07M. Therefore, the gross margin over that period was 96.2%.
QVCGA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, QVC Group Inc reported a gross profit of 608.00M and revenue of 2.68B. Therefore, the gross margin over that period was 22.7%.
KPTI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported an operating income of -26.76M and revenue of 35.07M, resulting in an operating margin of -76.3%.
QVCGA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, QVC Group Inc reported an operating income of 106.00M and revenue of 2.68B, resulting in an operating margin of 4.0%.
KPTI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a net income of -22.39M and revenue of 35.07M, resulting in a net margin of -63.9%.
QVCGA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, QVC Group Inc reported a net income of -37.00M and revenue of 2.68B, resulting in a net margin of -1.4%.
Find the right allocation for KPTI and QVCGA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer